Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
EARLY_PHASE1
Open-label pilot study to determine safety and efficacy of CART-19 cells in...
Status
Terminated
Location
Abramson Cancer Center of the University of Pennsylvania